Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib plus chemotherapy for untreated PTCL-associated HLH
ChiCTR2500102225Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golidocitinib in haemophagocytic lymphohistiocytosis (HLH) and peripheral T-cell lymphoma (PTCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 2-month survival rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2500102225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102225.